CREO — Creo Medical Income Statement
0.000.00%
Last trade - 00:00- £56.72m
- £52.42m
- £4.00m
Annual income statement for Creo Medical, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.43 | 25.2 | 27.2 | 4 | 4 |
| Cost of Revenue | |||||
| Gross Profit | 4.04 | 11.6 | 13.1 | 2.3 | 1.9 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 32.9 | 55.1 | 57.9 | 30.9 | 32.8 |
| Operating Profit | -23.5 | -29.9 | -30.8 | -26.9 | -28.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.5 | -30.3 | -31 | -26.4 | -29 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -20.3 | -24.6 | -26.9 | -23.7 | -27.8 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -20.3 | -24.6 | -26.9 | -21.7 | -28.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.3 | -24.6 | -26.9 | -21.7 | -28.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.125 | -0.144 | -0.143 | -0.076 | -0.075 |